tradmap

LNTH Lantheus Holdings, Inc.

$100.98 +0.17%

Updated

Healthcare · In Vitro & In Vivo Diagnostic Substances

Lantheus Holdings, Inc. (LNTH) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $6.6 billion. Shares last traded at $100.98, 9.7% below their 52-week high. Over the past year the stock is up 83.1%. LNTH trades at a price-to-earnings ratio of 23.94, below the In Vitro & In Vivo Diagnostic Substances median of 36.58. Net profit margin is 17.7%, above the peer median of -0.9%. Revenue grew 0.5% year over year.

Market Cap
$6.6B
Shares Out
65.3M
EPS (TTM)
$9.45
P/E Ratio
10.69
P/S Ratio
4.24
P/B Ratio
5.02
Dividend / Share
Dividend Yield
52-Week High
$111.84
52-Week Low
$49.74
Volume
43,585
Avg Vol (3m)
74,903.587

Performance

1W
+0.49%
1M
-0.46%
3M
-0.02%
6M
+32.31%
YTD
+50.09%
1Y
+83.07%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
47.96
SMA (50)
$103.24
SMA (200)
$83.96
Price vs SMA50
-2.19%
Price vs SMA200
+20.27%
ATR (14)
$1.39

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$1.6B
Net Income
$275M
Gross Margin
60.1%
Operating Margin
19.4%
Net Margin
17.7%
Return on Equity
21.0%
Return on Assets
11.4%
Current Ratio
3.06
Debt / Equity
0.43
Revenue Growth (YoY)
+0.5%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $2.91 2026-08-06
Q1 2026 $1.80 2026-05-07
FY 2025 $3.41 2026-02-26
Q3 2025 $2.60 2025-11-06
Q2 2026 $2.14 2026-08-06
Q1 2026 $1.02 2026-05-07

Full earnings history →

In Vitro & In Vivo Diagnostic Substances peers

LNTH vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap. Updated

P/E vs peers
23.94 / 36.58 med
-35% discount
P/S vs peers
4.24 / 4.24 med
+0% premium
Net margin vs peers
17.7% / -0.9% med
above median
1–14 of 14
IDXXIdexx Laboratories$41.7B36.589.1625.0%-1.81%
LNTHLantheus Holdings, Inc.$6.6B23.944.2417.7%+0.17%
CLDXCelldex Therapeutics, Inc.$3.1B-10.282000.34-0.32%
NEOGNeogen Corp$2.5B-322.002.92-0.9%-1.36%
NTLAIntellia Therapeutics, Inc.$1.8B-4.44-0.63%
QDELQuidelortho Corp$955M-0.910.36-39.2%-0.11%
ACHVAchieve Life Sciences, Inc.$855M-7.49-2.18%
TKNOAlpha Teknova, Inc.$388M-23.128.87-38.4%-2.83%
MYGNMyriad Genetics Inc$309M-2.740.38-14.0%-0.31%
IMDXInsight Molecular Diagnostics Inc.$135M-2.7433.41+2.99%
ICCCIMMUCELL CORP /DE/$90M114.192.932.6%-0.35%
QCLSQ/C TECHNOLOGIES, INC.$15M-0.939.79-1.57%
BMRABIOMERICA INC$10M-2.732.31-84.8%+2.51%
CDIOCardio Diagnostics Holdings, Inc.$5M-0.84374.80-1.08%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.